Menopause

Schiff, Isaac

Menopause. 17(1):1-2, January 2010.

doi: 10.1097/gme.0b013e3181c18195

Menopause. 17(1):23-24, January 2010.

doi: 10.1097/gme.0b013e3181cdd4a7

Menopause. 17(1):25-54, January 2010.

doi: 10.1097/gme.0b013e3181c617e6

In response to recent advances in the management and treatment of postmenopausal osteoporosis, The North American Menopause Society has made significant additions and modifications to its 2006 position statement.

Abstract:

Menopause. 17(1):55-56, January 2010.

doi: 10.1097/gme.0b013e3181cd64a8

Huang, Weng-Foung; Tsai, Yi-Wen; Wen, Yu-Wen; Hsiao, Fei-Yuan; Kuo, Ken N.; Tsai, Chia-Rung

Menopause. 17(1):57-63, January 2010.

doi: 10.1097/gme.0b013e3181b34749

No differences were found between alendronate and raloxifene on the risk of atrial fibrillation and flutter in women with osteoporosis. However, a significant association was found between long-term use of alendronate and increased risk of acute myocardial infarction in women with a history of cardiovascular events.

Abstract:

Taffe, John R.; Cain, Kevin C.; Mitchell, Ellen S.; Woods, Nancy F.; Crawford, Sybil L.; Harlow, Siobán D.

Menopause. 17(1):191-193, January 2010.

doi: 10.1097/gme.0b013e3181b5540e

Sixty-day amenorrhea first occurring to women aged 45 to 49 years predicts menopause within 5 years as well as does the traditional 90-day marker. Similar performance is associated with early recurrence of the 60-day marker for women to whom it first occurs in the age range 40 to 44 years.

Abstract:

Archer, David F.

Menopause. 17(1):194-203, January 2010.

doi: 10.1097/gme.0b013e3181a95581

Symptoms of urogenital atrophy are among the most common and most overlooked symptoms of postmenopausal estrogen deficiency. Numerous low-dose local vaginal estrogen therapies that effectively treat urogenital atrophy are available, but the optimal dose, duration, and mode of delivery may vary from woman to woman.

Abstract: